The Neuroscience of Being Human

The Neuroscience of GHB and GBL

How an endogenous neuromodulator became one of the most dangerous recreational drugs in the world, why the margin between euphoria and coma is measured in millilitres, and what the withdrawal syndrome reveals about GABA-B receptor dependence

1,540-word article with 8 Harvard references.

Endogenous molecule, exogenous danger

GHB occupies a pharmacological position unlike any other recreational drug: it is a substance that the brain manufactures for its own purposes. Maitre (1997), in the foundational review of GHB's endogenous role, documented that GHB is synthesised in the brain from GABA through the intermediate succinic semialdehyde, and is present in multiple brain regions at nanomolar concentrations. At these physiological levels, GHB binds to its own specific receptor, a G-protein-coupled receptor distinct from the GABA-A and GABA-B receptors, where it appears to modulate dopaminergic and glutamatergic neurotransmission. The physiological functions of endogenous GHB remain incompletely characterised, but evidence points to roles in sleep regulation, neuroprotection, and developmental neurobiology.

The problem begins when exogenous GHB is consumed at doses that exceed endogenous concentrations by several orders of magnitude. At recreational doses, typically one to three grams taken orally, GHB concentrations in the brain vastly exceed the binding capacity of the specific GHB receptor and begin to activate GABA-B receptors, producing a qualitatively different pharmacological effect. The transition from GHB receptor activation to GABA-B receptor activation is the transition from neuromodulation to sedation, and it occurs on a dose continuum so steep that the user may pass from one state to the other with a difference of less than a gram (Carter et al., 2009).

GABA-B agonism and the steepest dose-response curve in recreational pharmacology

Snead and Gibson (2005), writing in the New England Journal of Medicine, described GHB's dose-dependent pharmacological profile. At low recreational doses, the primary experience is euphoria, sociability, disinhibition, and mild sedation. These effects reflect moderate GABA-B activation combined with a secondary increase in dopamine release that GHB produces through a mechanism involving initial inhibition followed by rebound excitation of dopaminergic neurons. At slightly higher doses, sedation deepens rapidly. At doses only marginally above the euphoric range, consciousness is lost. The transition from awake and euphoric to unconscious is not gradual. It is abrupt, occurring over a narrow dose range that, when GHB is consumed as a liquid of variable concentration, can represent the difference of one or two millilitres.

Busardò and Jones (2015) documented the forensic pharmacology that makes this dose-response curve so dangerous. GHB follows zero-order elimination kinetics at recreational doses, meaning the body clears the drug at a fixed rate regardless of concentration, rather than the first-order kinetics that most drugs follow. The practical consequence is that once a dose exceeds the body's fixed clearance capacity, GHB accumulates rapidly. A dose that is twenty per cent above the euphoric threshold does not produce a proportionally modest increase in effect. It produces a disproportionate spike in blood concentration that tips the pharmacology from GABA-B mediated sedation into respiratory depression and coma. The combination of a steep dose-response curve and zero-order elimination makes GHB one of the easiest recreational drugs to accidentally overdose on, and the margin is made narrower still by the common practice of combining GHB with alcohol, which competes for the same metabolic pathways and further slows elimination.

GBL: the prodrug that arrives faster

GBL, gamma-butyrolactone, is not pharmacologically active itself. It is a lactone that is rapidly hydrolysed to GHB by peripheral lactonases in the blood, with conversion beginning within minutes of oral ingestion. Andresen et al. (2011) reviewed the pharmacokinetic differences between GHB and GBL and documented why GBL is the more dangerous delivery form. GBL is more lipophilic than GHB, meaning it crosses biological membranes more readily and is absorbed from the gastrointestinal tract more rapidly. The onset of effect is faster. The peak blood concentration of the resulting GHB is higher. And the subjective experience is perceived as more intense, leading users to describe GBL as stronger than GHB when in fact the molecule acting on the brain is identical. The difference is entirely pharmacokinetic: GBL gets more GHB to the brain faster.

GBL also has a practical property that amplifies its danger. It is an industrial solvent, legally available as a cleaning product, paint stripper, and chemical intermediate. In the United Kingdom, it is controlled as a Class C drug when intended for human consumption but remains legally available for industrial use. The result is a supply chain in which a substance that converts to one of the most dose-sensitive recreational drugs in pharmacology is available online, in hardware shops, and through industrial chemical suppliers, often at high purity and in large quantities. The user who measures their dose with a syringe may do so accurately. The user who estimates their dose by eye from a bottle of industrial solvent may not survive the estimation error.

Withdrawal: when GABA-B dependence produces a medical emergency

GHB withdrawal in dependent users is a medical emergency. McDonough et al. (2004) reviewed the clinical features and documented a syndrome that closely resembles severe alcohol withdrawal, which is pharmacologically coherent because both alcohol and GHB act on GABA-mediated inhibitory systems. Withdrawal symptoms begin within one to six hours of the last dose, reflecting GHB's short half-life. The initial symptoms are tremor, anxiety, tachycardia, hypertension, and insomnia. In moderate cases, these progress to nausea, vomiting, diaphoresis, and agitation. In severe cases, the syndrome escalates to delirium, visual and auditory hallucinations, psychosis, and seizures.

The severity of GHB withdrawal is related to the dosing pattern that chronic users adopt. Because GHB's half-life is approximately thirty to sixty minutes, dependent users typically dose every one to four hours, including through the night, setting alarms to prevent withdrawal symptoms from emerging during sleep. The result is a pattern of around-the-clock dosing that produces continuous GABA-B receptor activation and correspondingly profound receptor adaptation. When the drug is removed, the abrupt loss of GABA-B mediated inhibition produces a hyperexcitable state that can be life-threatening. Benzodiazepines, the standard treatment for alcohol withdrawal, are less effective for GHB withdrawal because they act on GABA-A rather than GABA-B receptors. Baclofen, a GABA-B agonist, has shown efficacy in managing GHB withdrawal by substituting at the same receptor, but the evidence base remains limited and management typically requires intensive care monitoring.

User populations and the chemsex context

Brennan and Van Hout (2014) reviewed the populations and contexts in which GHB and GBL use is concentrated. Three distinct user groups emerge from the literature. The first is the nightlife and club scene, where GHB is used for its euphoric and disinhibiting effects as an alternative to alcohol or MDMA. The second is the bodybuilding community, where GHB's stimulation of growth hormone release during sleep has made it popular as a purported performance-enhancing agent. The third, and increasingly prominent, is the chemsex context, where GHB and GBL are used in combination with methamphetamine and mephedrone to facilitate prolonged sexual sessions, often lasting days.

Liechti et al. (2016), studying the pharmacokinetics in controlled conditions, confirmed the steep dose-response curve and the narrow therapeutic window in healthy volunteers, providing the pharmacological basis for understanding why GHB-related emergency department presentations and fatalities have increased across Europe. The chemsex context adds particular danger because GHB is typically combined with other central nervous system depressants and stimulants, consumed in settings where measuring precision is impaired, and used in multi-day sessions where sleep deprivation further compromises judgement about dosing. The forensic literature documents numerous cases in which individuals have been found unconscious or dead after GHB use in these contexts, with blood concentrations only marginally above the range associated with recreational use.